The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Treatment for Communicable Diseases-Global Market Insights and Sales Trends 2024

Treatment for Communicable Diseases-Global Market Insights and Sales Trends 2024

Publishing Date : Nov, 2023

License Type :
 

Report Code : 1838584

No of Pages : 111

Synopsis
In this report, we study the drugs for Communicable Diseases. Communicable diseases are disorders caused by organisms — such as bacteria, viruses,fungi or parasites
The global Treatment for Communicable Diseases market size is expected to reach US$ 68580 million by 2029, growing at a CAGR of 6.6% from 2023 to 2029. The market is mainly driven by the significant applications of Treatment for Communicable Diseases in various end use industries. The expanding demands from the Hospital, Clinic and Other, are propelling Treatment for Communicable Diseases market. HIV, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Influenza segment is estimated at % CAGR for the next seven-year period.
The Communicable Diseases Treatment market refers to the pharmaceuticals and treatments used for the management and control of infectious diseases that can be transmitted from person to person. This market includes antiviral drugs, antibiotics, vaccines, and other therapies. The Communicable Diseases Treatment market has experienced significant growth due to factors such as the increasing prevalence of infectious diseases, the emergence of new pathogens, and the need for effective treatment options. Key players in the market include pharmaceutical companies, biotechnology firms, and government healthcare agencies. Geographically, the market is diverse, with regions facing different communicable disease burdens.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Treatment for Communicable Diseases, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Treatment for Communicable Diseases market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Treatment for Communicable Diseases market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Treatment for Communicable Diseases sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Treatment for Communicable Diseases covered in this report include Novartis, Gilead, GSK, Roche, Merck, Boehringer Ingelheim, Eli Lilly, AstraZeneca and J & J, etc.
The global Treatment for Communicable Diseases market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Gilead
GSK
Roche
Merck
Boehringer Ingelheim
Eli Lilly
AstraZeneca
J & J
Teva
AbbVie
Bausch Health
Abbott
Sanofi
Sun Pharma
Endo
Apotex
Amneal Pharma
Torrent Pharma
Global Treatment for Communicable Diseases market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Treatment for Communicable Diseases market, Segment by Type:
HIV
Influenza
TB
Malaria
Hepatitis
HPV
Global Treatment for Communicable Diseases market, by Application
Hospital
Clinic
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Treatment for Communicable Diseases companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index
1 Market Overview of Treatment for Communicable Diseases
1.1 Treatment for Communicable Diseases Market Overview
1.1.1 Treatment for Communicable Diseases Product Scope
1.1.2 Treatment for Communicable Diseases Market Status and Outlook
1.2 Global Treatment for Communicable Diseases Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Treatment for Communicable Diseases Market Size by Region (2018-2029)
1.4 Global Treatment for Communicable Diseases Historic Market Size by Region (2018-2023)
1.5 Global Treatment for Communicable Diseases Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Treatment for Communicable Diseases Market Size (2018-2029)
1.6.1 North America Treatment for Communicable Diseases Market Size (2018-2029)
1.6.2 Europe Treatment for Communicable Diseases Market Size (2018-2029)
1.6.3 Asia-Pacific Treatment for Communicable Diseases Market Size (2018-2029)
1.6.4 Latin America Treatment for Communicable Diseases Market Size (2018-2029)
1.6.5 Middle East & Africa Treatment for Communicable Diseases Market Size (2018-2029)
2 Treatment for Communicable Diseases Market by Type
2.1 Introduction
2.1.1 HIV
2.1.2 Influenza
2.1.3 TB
2.1.4 Malaria
2.1.5 Hepatitis
2.1.6 HPV
2.2 Global Treatment for Communicable Diseases Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Treatment for Communicable Diseases Historic Market Size by Type (2018-2023)
2.2.2 Global Treatment for Communicable Diseases Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Treatment for Communicable Diseases Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Treatment for Communicable Diseases Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Treatment for Communicable Diseases Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Treatment for Communicable Diseases Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Treatment for Communicable Diseases Revenue Breakdown by Type (2018-2029)
3 Treatment for Communicable Diseases Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Clinic
3.1.3 Other
3.2 Global Treatment for Communicable Diseases Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Treatment for Communicable Diseases Historic Market Size by Application (2018-2023)
3.2.2 Global Treatment for Communicable Diseases Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Treatment for Communicable Diseases Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Treatment for Communicable Diseases Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Treatment for Communicable Diseases Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Treatment for Communicable Diseases Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Treatment for Communicable Diseases Revenue Breakdown by Application (2018-2029)
4 Treatment for Communicable Diseases Competition Analysis by Players
4.1 Global Treatment for Communicable Diseases Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Treatment for Communicable Diseases as of 2022)
4.3 Date of Key Players Enter into Treatment for Communicable Diseases Market
4.4 Global Top Players Treatment for Communicable Diseases Headquarters and Area Served
4.5 Key Players Treatment for Communicable Diseases Product Solution and Service
4.6 Competitive Status
4.6.1 Treatment for Communicable Diseases Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Novartis
5.1.1 Novartis Profile
5.1.2 Novartis Main Business
5.1.3 Novartis Treatment for Communicable Diseases Products, Services and Solutions
5.1.4 Novartis Treatment for Communicable Diseases Revenue (US$ Million) & (2018-2023)
5.1.5 Novartis Recent Developments
5.2 Gilead
5.2.1 Gilead Profile
5.2.2 Gilead Main Business
5.2.3 Gilead Treatment for Communicable Diseases Products, Services and Solutions
5.2.4 Gilead Treatment for Communicable Diseases Revenue (US$ Million) & (2018-2023)
5.2.5 Gilead Recent Developments
5.3 GSK
5.3.1 GSK Profile
5.3.2 GSK Main Business
5.3.3 GSK Treatment for Communicable Diseases Products, Services and Solutions
5.3.4 GSK Treatment for Communicable Diseases Revenue (US$ Million) & (2018-2023)
5.3.5 Roche Recent Developments
5.4 Roche
5.4.1 Roche Profile
5.4.2 Roche Main Business
5.4.3 Roche Treatment for Communicable Diseases Products, Services and Solutions
5.4.4 Roche Treatment for Communicable Diseases Revenue (US$ Million) & (2018-2023)
5.4.5 Roche Recent Developments
5.5 Merck
5.5.1 Merck Profile
5.5.2 Merck Main Business
5.5.3 Merck Treatment for Communicable Diseases Products, Services and Solutions
5.5.4 Merck Treatment for Communicable Diseases Revenue (US$ Million) & (2018-2023)
5.5.5 Merck Recent Developments
5.6 Boehringer Ingelheim
5.6.1 Boehringer Ingelheim Profile
5.6.2 Boehringer Ingelheim Main Business
5.6.3 Boehringer Ingelheim Treatment for Communicable Diseases Products, Services and Solutions
5.6.4 Boehringer Ingelheim Treatment for Communicable Diseases Revenue (US$ Million) & (2018-2023)
5.6.5 Boehringer Ingelheim Recent Developments
5.7 Eli Lilly
5.7.1 Eli Lilly Profile
5.7.2 Eli Lilly Main Business
5.7.3 Eli Lilly Treatment for Communicable Diseases Products, Services and Solutions
5.7.4 Eli Lilly Treatment for Communicable Diseases Revenue (US$ Million) & (2018-2023)
5.7.5 Eli Lilly Recent Developments
5.8 AstraZeneca
5.8.1 AstraZeneca Profile
5.8.2 AstraZeneca Main Business
5.8.3 AstraZeneca Treatment for Communicable Diseases Products, Services and Solutions
5.8.4 AstraZeneca Treatment for Communicable Diseases Revenue (US$ Million) & (2018-2023)
5.8.5 AstraZeneca Recent Developments
5.9 J & J
5.9.1 J & J Profile
5.9.2 J & J Main Business
5.9.3 J & J Treatment for Communicable Diseases Products, Services and Solutions
5.9.4 J & J Treatment for Communicable Diseases Revenue (US$ Million) & (2018-2023)
5.9.5 J & J Recent Developments
5.10 Teva
5.10.1 Teva Profile
5.10.2 Teva Main Business
5.10.3 Teva Treatment for Communicable Diseases Products, Services and Solutions
5.10.4 Teva Treatment for Communicable Diseases Revenue (US$ Million) & (2018-2023)
5.10.5 Teva Recent Developments
5.11 AbbVie
5.11.1 AbbVie Profile
5.11.2 AbbVie Main Business
5.11.3 AbbVie Treatment for Communicable Diseases Products, Services and Solutions
5.11.4 AbbVie Treatment for Communicable Diseases Revenue (US$ Million) & (2018-2023)
5.11.5 AbbVie Recent Developments
5.12 Bausch Health
5.12.1 Bausch Health Profile
5.12.2 Bausch Health Main Business
5.12.3 Bausch Health Treatment for Communicable Diseases Products, Services and Solutions
5.12.4 Bausch Health Treatment for Communicable Diseases Revenue (US$ Million) & (2018-2023)
5.12.5 Bausch Health Recent Developments
5.13 Abbott
5.13.1 Abbott Profile
5.13.2 Abbott Main Business
5.13.3 Abbott Treatment for Communicable Diseases Products, Services and Solutions
5.13.4 Abbott Treatment for Communicable Diseases Revenue (US$ Million) & (2018-2023)
5.13.5 Abbott Recent Developments
5.14 Sanofi
5.14.1 Sanofi Profile
5.14.2 Sanofi Main Business
5.14.3 Sanofi Treatment for Communicable Diseases Products, Services and Solutions
5.14.4 Sanofi Treatment for Communicable Diseases Revenue (US$ Million) & (2018-2023)
5.14.5 Sanofi Recent Developments
5.15 Sun Pharma
5.15.1 Sun Pharma Profile
5.15.2 Sun Pharma Main Business
5.15.3 Sun Pharma Treatment for Communicable Diseases Products, Services and Solutions
5.15.4 Sun Pharma Treatment for Communicable Diseases Revenue (US$ Million) & (2018-2023)
5.15.5 Sun Pharma Recent Developments
5.16 Endo
5.16.1 Endo Profile
5.16.2 Endo Main Business
5.16.3 Endo Treatment for Communicable Diseases Products, Services and Solutions
5.16.4 Endo Treatment for Communicable Diseases Revenue (US$ Million) & (2018-2023)
5.16.5 Endo Recent Developments
5.17 Apotex
5.17.1 Apotex Profile
5.17.2 Apotex Main Business
5.17.3 Apotex Treatment for Communicable Diseases Products, Services and Solutions
5.17.4 Apotex Treatment for Communicable Diseases Revenue (US$ Million) & (2018-2023)
5.17.5 Apotex Recent Developments
5.18 Amneal Pharma
5.18.1 Amneal Pharma Profile
5.18.2 Amneal Pharma Main Business
5.18.3 Amneal Pharma Treatment for Communicable Diseases Products, Services and Solutions
5.18.4 Amneal Pharma Treatment for Communicable Diseases Revenue (US$ Million) & (2018-2023)
5.18.5 Amneal Pharma Recent Developments
5.19 Torrent Pharma
5.19.1 Torrent Pharma Profile
5.19.2 Torrent Pharma Main Business
5.19.3 Torrent Pharma Treatment for Communicable Diseases Products, Services and Solutions
5.19.4 Torrent Pharma Treatment for Communicable Diseases Revenue (US$ Million) & (2018-2023)
5.19.5 Torrent Pharma Recent Developments
6 North America
6.1 North America Treatment for Communicable Diseases Market Size by Country (2018-2029)
6.2 the United States
6.3 Canada
7 Europe
7.1 Europe Treatment for Communicable Diseases Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Treatment for Communicable Diseases Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Treatment for Communicable Diseases Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Treatment for Communicable Diseases Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Treatment for Communicable Diseases Market Dynamics
11.1 Treatment for Communicable Diseases Industry Trends
11.2 Treatment for Communicable Diseases Market Drivers
11.3 Treatment for Communicable Diseases Market Challenges
11.4 Treatment for Communicable Diseases Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

Published By : QY Research

Why ‘The Market Reports’